![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sciele Pharma (MM) | NASDAQ:SCRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0 | - |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
(Rule 14d-101)
(Amendment No. 1)
Solicitation/Recommendation Statement
under Section 14(d)(4)
of the Securities Exchange Act of 1934
SCIELE PHARMA, INC.
(Name of Subject Company)
SCIELE PHARMA, INC.
(Name of Person(s) Filing Statement)
Common Stock, $0.001 par value per share
(Title or Class of Securities)
808627103
(CUSIP Number of Class of Securities)
Patrick P. Fourteau
Chief Executive Officer
Sciele Pharma, Inc.
5 Concourse Parkway, Suite 1800
Atlanta, Georgia 30328
(770) 442-9707
(Name, address and telephone number of person authorized
to receive notices and communications on behalf of the person(s) filing statement)
With a copy to:
W. Tinley Anderson, III, Esq.
Paul, Hastings, Janofsky & Walker LLP
600 Peachtree St., N. E., Suite 2400
Atlanta, GA 30308
(404) 815-2400
o Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
This Amendment No. 1 amends and supplements Item 8 in the Solicitation/Recommendation Statement on Schedule 14D-9 (the Schedule) initially filed with the U.S. Securities and Exchange Commission on September 8, 2008, by Sciele Pharma, Inc., a Delaware corporation (Sciele). This Schedule relates to the tender offer by Tall Bridge, Inc., a Delaware corporation (Purchaser) and an indirect wholly-owned subsidiary of Shionogi & Co., Ltd., a company organized under the laws of Japan (Parent), to purchase all of the issued and outstanding shares of Sciele common stock at a price per share of $31.00, net to the holder thereof in cash, without interest thereon, subject to any required withholding of taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated September 8, 2008, and the related Letter of Transmittal, as each may be amended or supplemented from time to time.
All information in the Schedule is incorporated by reference in this Amendment No. 1, except that such information is hereby amended and supplemented to the extent specifically provided herein. Except as otherwise indicated, the information set forth in the original Schedule 14D-9 remains unchanged. Capitalized terms used below but not defined in this Amendment No. 1 have the meanings set forth in the Schedule.
Item 8. Additional Information.
Item 8 is hereby amended and supplemented by adding the following under Antitrust The United States:
At 11:59 p.m. on Thursday, September 18, 2008, the waiting period applicable to the Offer and the Merger under the HSR Act expired. Accordingly, the condition to the Offer that any waiting period under the HSR Act shall have expired has been satisfied.
Item 9. Exhibits
Item 9 is hereby amended and supplemented as follows:
Exhibit No. |
|
Description |
|
|
|
(a)(10) |
|
Joint Press Release issued by Parent and Sciele dated September 19, 2008.* |
*Filed herewith.
2
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: September 19, 2008 |
SCIELE PHARMA, INC. |
|
|
By: |
|
|
|
|
|
|
|
|
|
/s/ Patrick P. Fourteau |
|
|
Name: Patrick P. Fourteau |
|
|
Title: Chief Executive Officer |
3
1 Year Sciele Pharma (MM) Chart |
1 Month Sciele Pharma (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions